Amniotics Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
Amniotics's earnings have been declining at an average annual rate of -15.9%, while the Biotechs industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 169.3% per year.
Key information
-15.9%
Earnings growth rate
45.1%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | 169.3% |
Return on equity | -198.7% |
Net Margin | n/a |
Next Earnings Update | 20 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Amniotics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -31 | 32 | 0 |
30 Sep 23 | 0 | -35 | 34 | 0 |
30 Jun 23 | 0 | -45 | 42 | 0 |
31 Mar 23 | 0 | -49 | 45 | 0 |
31 Dec 22 | 0 | -48 | 45 | 0 |
30 Sep 22 | 0 | -51 | 48 | 0 |
30 Jun 22 | 0 | -45 | 43 | 0 |
31 Mar 22 | 0 | -52 | 50 | 0 |
31 Dec 21 | 0 | -54 | 51 | 0 |
30 Sep 21 | 0 | -54 | 53 | 0 |
30 Jun 21 | 0 | -50 | 48 | 0 |
31 Mar 21 | 0 | -38 | 40 | 0 |
31 Dec 20 | 0 | -31 | 29 | 0 |
31 Dec 19 | 0 | -10 | 10 | 0 |
31 Dec 18 | 0 | -7 | 7 | 0 |
Quality Earnings: 66J is currently unprofitable.
Growing Profit Margin: 66J is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 66J is unprofitable, and losses have increased over the past 5 years at a rate of 15.9% per year.
Accelerating Growth: Unable to compare 66J's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 66J is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: 66J has a negative Return on Equity (-198.66%), as it is currently unprofitable.